Nananda F Col

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi The use of gene tests to detect hereditary predisposition to chronic disease: is cost-effectiveness analysis relevant?
    Nananda F Col
    Division of Women s Health, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Med Decis Making 23:441-8. 2003
  2. ncbi The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience?
    Nananda F Col
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, and Tufts New England Medical Center, Boston, Massachusetts 02120, USA
    Ann Intern Med 139:923-9. 2003
  3. ncbi Commentary--surgical decisions after breast cancer: can patients be too involved in decision making?
    Nananda F Col
    Department of Medicine, Brown Medical School and Rhode Island Hospital, MPB 1, 593 Eddy St, Providence, Rhode Island 02903, USA
    Health Serv Res 40:769-79. 2005
  4. ncbi Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making
    Ellen T Matloff
    Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut 06520, USA
    J Womens Health (Larchmt) 15:843-56. 2006
  5. ncbi Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence
    Nananda F Col
    Brown Medical School, Providence, Rhode Island, USA
    Breast Cancer Res 7:R535-40. 2005
  6. ncbi Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model
    Nananda F Col
    Med Decis Making 22:386-93. 2002
  7. ncbi Using Internet technologies to improve and simplify counseling about menopause: the WISDOM website
    Nananda F Col
    Brown University, Providence, RI, United States
    Maturitas 57:95-9. 2007
  8. ncbi Short-term menopausal hormone therapy for symptom relief: an updated decision model
    Nananda F Col
    Division of General Internal Medicine, Rhode Island Hospital, Brown Medical School, Providence 02903, USA
    Arch Intern Med 164:1634-40. 2004
  9. ncbi Meta-analysis of vascular and neoplastic events associated with tamoxifen
    R Scott Braithwaite
    Section of Clinical Systems Modeling, Division of General Internal Medicine, Department of Medicne, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Gen Intern Med 18:937-47. 2003
  10. ncbi Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy
    Rowan T Chlebowski
    Harbor-UCLA Research and Education Institute, Torrance 90502, USA
    Semin Oncol 30:776-88. 2003

Detail Information

Publications11

  1. ncbi The use of gene tests to detect hereditary predisposition to chronic disease: is cost-effectiveness analysis relevant?
    Nananda F Col
    Division of Women s Health, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Med Decis Making 23:441-8. 2003
    ..CEAs do not seem to have played an important role in identifying whom to offer genetic testing nor how to manage those found to carry the gene marker. Credible CEAs are needed to provide guidance about screening decisions...
  2. ncbi The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience?
    Nananda F Col
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, and Tufts New England Medical Center, Boston, Massachusetts 02120, USA
    Ann Intern Med 139:923-9. 2003
    ..Beliefs held by patients, clinicians, and investigators might have affected the ascertainment of CHD outcomes in observational studies...
  3. ncbi Commentary--surgical decisions after breast cancer: can patients be too involved in decision making?
    Nananda F Col
    Department of Medicine, Brown Medical School and Rhode Island Hospital, MPB 1, 593 Eddy St, Providence, Rhode Island 02903, USA
    Health Serv Res 40:769-79. 2005
  4. ncbi Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making
    Ellen T Matloff
    Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut 06520, USA
    J Womens Health (Larchmt) 15:843-56. 2006
    ..The authors determined the effects of a personalized risk assessment and genetic counseling intervention on knowledge, risk perception, and decision making in a group of healthy women who had a first-degree relative with breast cancer...
  5. ncbi Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence
    Nananda F Col
    Brown Medical School, Providence, Rhode Island, USA
    Breast Cancer Res 7:R535-40. 2005
    ..Our objectives were to estimate the effects of HT on recurrence in breast cancer survivors and to examine the reliability of these estimates...
  6. ncbi Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model
    Nananda F Col
    Med Decis Making 22:386-93. 2002
    ..However, this benefit is modulated in women at increased endometrial cancer risk and depends on assumptions concerning tamoxifen's lingering effects on breast and endometrial cancer...
  7. ncbi Using Internet technologies to improve and simplify counseling about menopause: the WISDOM website
    Nananda F Col
    Brown University, Providence, RI, United States
    Maturitas 57:95-9. 2007
    ..Preliminary trial results suggest a positive impact on clinicians and patients. The unique challenges and opportunities in developing and testing web-based decision support tools are discussed...
  8. ncbi Short-term menopausal hormone therapy for symptom relief: an updated decision model
    Nananda F Col
    Division of General Internal Medicine, Rhode Island Hospital, Brown Medical School, Providence 02903, USA
    Arch Intern Med 164:1634-40. 2004
    ..Our objective was to identify which women should benefit from short-term HT by exploring the trade-off between symptom relief and risks of inducing disease...
  9. ncbi Meta-analysis of vascular and neoplastic events associated with tamoxifen
    R Scott Braithwaite
    Section of Clinical Systems Modeling, Division of General Internal Medicine, Department of Medicne, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Gen Intern Med 18:937-47. 2003
    ..Our purpose was to estimate the effects of tamoxifen on potentially life-threatening vascular and neoplastic outcomes...
  10. ncbi Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy
    Rowan T Chlebowski
    Harbor-UCLA Research and Education Institute, Torrance 90502, USA
    Semin Oncol 30:776-88. 2003
    ....
  11. ncbi Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: a framework for personalized risk assessment and counseling
    Ellen T Matloff
    Cancer Genetic Counseling, Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA
    J Cancer Educ 22:10-4. 2007
    ..Current models in use do not include pedigree analysis, personalized risk assessment, or genetic testing in this process...